Client News

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome

Motif Bio plc: Proposed Equity Fundraise

Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II

MagForce AG successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland

Breath Therapeutics Announces Presentations at Upcoming Scientific Conferences

Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim

Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912

MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

AiCuris plant sein weiteres Wachstum in Wuppertal